• Clinical Insights: April 1, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Zeposia® (ozanimod) Capsules – New Drug Approval – March 26, 2020 – Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved Zeposia® (ozanimod) 0.92… Read more »

  • Clinical Insights: March 24, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Isturisa® (osilodrostat) Tablets – New Orphan Drug Approval – March 6, 2020 – The U.S. Food and Drug Administration announced the approval of Isturisa® (osilodrostat)… Read more »

  • Happy Holidays!

      Happy Holidays from the RxStrategies team! Wishing you a time filled with fun and joy. Best wishes for the New Year!   Warm Regards, The RxStrategies Team

  • Clinical Insights: September 30, 2019

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Jynneos™ (smallpox and monkeypox vaccine, live, nonreplicating) – New Vaccine Approval – September 24, 2019 – The U.S. Food and Drug Administration announced the approval… Read more »

  • Let’s Connect: APHCA Annual Conference and Expo

    RxStrategies is proud to be a Platinum Presenting Sponsor of Alabama Primary Health Care Association’s (APHCA) Annual Bootcamp, Conference and Expo. The event is the State’s largest annual gathering of community health systems, providers and partners from across the community of care. This year’s annual event, Taking Point, will be held on October 1-3, 2019 at… Read more »

  • Clinical Insights: September 13, 2019

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Ibsrela® (tenapanor) – New Drug Approval – September 12, 2019 – Ardelyx, Inc., announced that the U.S. Food and Drug Administration has approved Ibsrela®… Read more »

  • 340B Insider – August 2019

                    Welcome to the August edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. Visit our website to read more.           RECAP: 340B COALITION SUMMER CONFERENCE It was great to connect with so many of our clients and industry leaders… Read more »

  • Clinical Insights: August 29, 2019

    Welcome to RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.   New Drug Approval Nourianz™ (istradefylline) – New Drug Approval – August 27, 2019 – The U.S. Food and Drug Administration approved Nourianz™ (istradefylline) tablets as an add-on treatment… Read more »